Grade @ or higher adverse events that occurred in more than @ % of patients in the ramucirumab plus paclitaxel group versus placebo plus paclitaxel included neutropenia ( @ -LSB- @ % -RSB- of @ vs @ -LSB- @ % -RSB- of @ ) , leucopenia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , hypertension ( @ -LSB- @ % -RSB- vs eight -LSB- @ % -RSB- ) , fatigue ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , anaemia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , and abdominal pain ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) .